Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
Finch Therapeutics (Nasdaq: FNCH) has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Finch Therapeutics (Nasdaq: FNCH) has announced its participation in two upcoming investor conferences. The Jefferies London Healthcare Conference will feature a corporate presentation by Chief Medical Officer Howard Franklin on November 16, 2022. The Evercore ISI HealthCONx Conference will include a fireside chat with CEO Mark Smith on December 1, 2022. Live webcasts of both presentations will be available on Finch's website, with replays accessible for 30 days. Finch is known for its innovative microbiome therapeutics and is advancing its lead candidate, CP101, for recurrent C. difficile infections.
Details
News Market Reaction – FNCH
The recorded move for FNCH in the trading session of this news was -5.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences:
- Jefferies London Healthcare Conference
Wednesday, November 16, 2022 at 10:55 am GMT
Corporate presentation by Howard Franklin, MD, MBA, Chief Medical Officer
- Evercore ISI HealthCONx Conference
Thursday, December 1, 2022 at 11:20 am ET
Fireside chat with Mark Smith, PhD, Chief Executive Officer
Live webcasts of both events will be available under the ‘Investors & News’ section of the Finch website. Replays of the webcasts will be available on Finch’s website for approximately 30 days after each event.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is exploring strategic options to potentially advance the development of its pre-clinical candidates FIN-524 for ulcerative colitis and FIN-525 for Crohn's disease and its pre-clinical program in autism spectrum disorder. Finch routinely posts information that may be important to its investors on its website at www.finchtherapeutics.com. Finch encourages investors to consult the “Investors & News” section of its website regularly.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.